Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Authors
Keywords
-
Journal
BMC CANCER
Volume 12, Issue 1, Pages -
Publisher
Springer Nature
Online
2012-03-23
DOI
10.1186/1471-2407-12-104
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers with Predictive and Prognostic Function in Non–Small Cell Lung Cancer: Ready for Prime Time?
- (2017) Charu Aggarwal et al. Journal of the National Comprehensive Cancer Network
- Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
- (2015) Hayato Fujita et al. NEOPLASIA
- ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis
- (2011) Gerold Bepler et al. AMERICAN JOURNAL OF PATHOLOGY
- Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer
- (2011) Richard Kim et al. CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thymidine synthase, thymidine phosphorylase and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
- (2010) S Lee et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)
- (2010) Jae Jin Lee et al. LUNG CANCER
- pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs
- (2010) Timothy K. Williams et al. PLoS One
- In SituProtein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy
- (2009) G. Metro et al. CANCER INVESTIGATION
- The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
- (2009) C. L. Costantino et al. CANCER RESEARCH
- Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer
- (2009) Craig Reynolds et al. JOURNAL OF CLINICAL ONCOLOGY
- Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma
- (2009) H Akita et al. ONCOGENE
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
- (2008) Volker Heinemann et al. BMC CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started